Compiled by KMI Media Group staff
EMS Solutions with Latest Evolution of the Defibrillator
Philips has introduced the tactically enhanced HeartStart MRx monitor/ defibrillator for emergency medical services (EMS). Designed in collaboration with EMS professionals, the latest enhancements will further help professional responders improve and save lives. EMS professionals require easy to use, technically advanced monitors to focus on what matters most: patient care. With a commitment to meaningful innovation, Philips is introducing numerous improvements in the HeartStart MRx monitor/ defibrillators. The newest innovations are based on extensive feedback from EMS professionals. Each enhancement is designed to help professional responders optimize workflow and include: • • • • • •
Tactical gray color option designed to show less dirt and wear over time Automatic lead switching, which allows users to focus on the patient, not the monitor Improved ECG performance, including new ‘ruggedized’ EMS lead sets Flexible event summary print options for enhanced workflow Enhanced event markers, with the ability to enter drug dose and unit of measure Auto switching from demand-mode to fixed-mode pacing if the primary ECG lead is lost
The HeartStart MRx combines industry-leading monitoring technology with diagnostic measurements and Philips’ patented defibrillation therapies in a rugged, lightweight device. The HeartStart MRx provides several advanced features important to EMS professionals, including Philips’ advanced DXL 12-Lead ECG algorithm, a large color display, fast time to shock and the longest battery operating time for ECG monitoring among eight leading monitor/defibrillators, according to published manufacturer’s specifications. Additionally, Q-CPR, the most clinically proven CPR measurement and feedback tool, is available as a fully integrated option. Brian Healey; brian.healey@philips.com
www.M2VA-kmi.com
Blood Glucose Monitoring System Receives FDA Clearance Abbott recently announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System, the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers. The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months. According to the American Diabetes Association (ADA), approximately 25.8 million people in the United States have diabetes, and of those, many require insulin to manage their condition. The FreeStyle InsuLinx System is the newest addition to Abbott’s portfolio of glucose monitoring systems and is designed to use FreeStyle technology to help insulin-using patients monitor their blood glucose levels to allow them to more effectively manage their condition. Specifically, the FreeStyle InsuLinx System offers: • • •
•
Touch screen designed for ease of use Automated logbook that assists with tracking logged insulin doses and blood glucose levels Personalization features, including the ability to upload weekly messages, pre-and post-meal markers and a personal photograph to the home screen FreeStyle Auto-Assist software that can be uploaded to a computer via USB connectivity and is designed to help people with diabetes, health care teams and caregivers manage diabetes with reports, reminders and messages
The FreeStyle InsuLinx System is compatible with the FreeStyle InsuLinx blood glucose test strips. “The new FreeStyle InsuLinx System represents Abbott’s latest advancement in delivering innovative products for people with diabetes who use insulin,” said Heather L. Mason, senior vice president, Abbott Diabetes Care. “The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States.” Daniel Moberly; daniel.moberly@abbott.com
M2VA 16.3 | 15